World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
39382
World Ranking
10349
National Ranking
5323

Hedy L. Kindler publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hedy L. Kindler sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 515 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hedy L. Kindler D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hedy L. Kindler sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hedy L. Kindler is affiliated with the University of Chicago in the United States, contributing extensively to medical research with a focus on oncology. Their body of work encompasses over 300 publications predominantly in the field of medicine, with particular emphasis on oncology and pulmonary and respiratory medicine.

Their research spans various subfields including oncology, pulmonary and respiratory medicine, cancer research, surgery, and radiology, nuclear medicine, and imaging. Key topics covered by their research include occupational and environmental lung diseases, pancreatic and hepatic oncology, pleural and pulmonary diseases, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, PARP inhibition in cancer therapy, and cancer research and treatments.

Notable recent publications by Hedy L. Kindler include:

  • Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2022, Journal of Clinical Oncology)
  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation (2020, Journal of Clinical Oncology)
  • First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors (2020, Journal of Clinical Oncology)
  • Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial (2021, Nature Medicine)

Hedy L. Kindler frequently publishes in the following venues:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • UNC Libraries
  • Annals of Oncology
  • Annals of Surgical Oncology

Frequent coauthors with whom Kindler has collaborated include:

  • Talia Golan
  • Eileen M. O'Reilly
  • Gershon Y. Locker
  • Kiran K. Turaga
  • David McGuinness

Their work in oncology research touches on clinical trials, biomarker analysis, and novel cancer therapeutics. The research outputs also indicate involvement in advanced therapies for pancreatic cancer, mesothelioma, and solid tumors, with an interdisciplinary approach combining clinical oncology, genomics, and pharmacological treatments.

Best Publications

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

    Hedy L. Kindler;Gregory Friberg;Deepti A. Singh;Gershon Locker

  • Integrative Molecular Characterization of Malignant Pleural Mesothelioma

    Julija Hmeljak;Francisco Sanchez-Vega;Katherine A. Hoadley;Juliann Shih

  • Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma

    Lee M. Krug;Harvey I. Pass;Valerie W. Rusch;Hedy L. Kindler

  • Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

    Raffit Hassan;Susie Bullock;Ahalya Premkumar;Robert J. Kreitman

  • Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

    Leonard B. Saltz;Heinz-Josef Lenz;Hedy L. Kindler;Howard S. Hochster

  • Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    Daniel V.T. Catenacci;Melissa R. Junttila;Theodore Karrison;Nathan Bahary

  • Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

    Matthew H.G. Katz;Qian Shi;Syed A. Ahmad;Joseph M. Herman

  • Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

    Michele Maio;Arnaud Scherpereel;Luana Calabrò;Joachim Aerts

  • Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

    Hedy L Kindler;Tatsuya Ioka;Dirk J Richel;Jaafar Bennouna

  • Malignant pleural mesothelioma

    Anne S. Tsao;Ignacio Wistuba;Jack A. Roth;Hedy Lee Kindler

  • Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

    Rudolph M. Navari;Rick R. Reinhardt;Richard J. Gralla;Mark G. Kris

  • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

    Helmut Oettle;D. Richards;R. K. Ramanathan;J. L. van Laethem

  • Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

    Hedy L. Kindler;Nofisat Ismaila;Samuel G. Armato;Raphael Bueno

  • Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

    Giorgio V. Scagliotti;Dong-M. Shin;Hedy L. Kindler;Michael J. Vasconcelles

  • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

    H. L. Kindler;D. Niedzwiecki;D. Hollis;E. Oraefo

Frequent Co-Authors

Theodore Karrison
Theodore Karrison University of Chicago
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Alan P. Venook
Alan P. Venook University of California, San Francisco
Everett E. Vokes
Everett E. Vokes University of Chicago
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Ravi Salgia
Ravi Salgia City Of Hope National Medical Center
Anna K. Nowak
Anna K. Nowak University of Western Australia
Walter M. Stadler
Walter M. Stadler University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t have to follow a single path. Today, there are many pharmacy school online accredited options that allow students to earn a pharmacy degree with more flexibility and often at a lower cost.

For those interested in the management side of healthcare, pursuing an online mhi (Master of Health Information) can lead to rewarding roles in hospitals, clinics, and health organizations, focusing on data and record management.

Technology-driven careers such as medical coding and billing are also in high demand. By enrolling in a low cost medical coding and billing online program, you can quickly enter the workforce and support the healthcare system from an administrative perspective.

Additionally, becoming an advanced practice provider is possible through flexible nurse practitioner programs, offering pathways to clinical careers with strong growth and impact.

Whether pursuing direct patient care or support roles, these online degrees open doors to diverse and evolving healthcare careers.

Best Scientists Citing Hedy L. Kindler

Trending Scientists

Recently Published Articles